Cargando…

Stenotrophomonas Bacteremia Antibiotic Susceptibility and Prognostic Determinants: Mayo Clinic 10-Year Experience

BACKGROUND: Stenotrophomonas maltophilia is a gram-negative, opportunistic infection that is usually hospital-acquired and associated with high morbidity and mortality. The reported increase in S. maltophilia infections is presumed to be due to an increase in the population at risk. METHODS: We retr...

Descripción completa

Detalles Bibliográficos
Autores principales: Hamdi, Ahmed M, Fida, Madiha, Abu Saleh, Omar M, Beam, Elena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6988836/
https://www.ncbi.nlm.nih.gov/pubmed/32016126
http://dx.doi.org/10.1093/ofid/ofaa008
_version_ 1783492324521672704
author Hamdi, Ahmed M
Fida, Madiha
Abu Saleh, Omar M
Beam, Elena
author_facet Hamdi, Ahmed M
Fida, Madiha
Abu Saleh, Omar M
Beam, Elena
author_sort Hamdi, Ahmed M
collection PubMed
description BACKGROUND: Stenotrophomonas maltophilia is a gram-negative, opportunistic infection that is usually hospital-acquired and associated with high morbidity and mortality. The reported increase in S. maltophilia infections is presumed to be due to an increase in the population at risk. METHODS: We retrospectively reviewed 10-year data for S. maltophilia bacteremia in hospitalized adults at our institution to determine the population at risk, sources of infection, common complications, antimicrobial susceptibility profiles, and clinical outcome trends over the past decade. RESULTS: Among the 98 patients analyzed, the most common source of infection was catheter-related (62, 63.3%). Most isolates (61, 65%) were resistant to ceftazidime; fewer were resistant to trimethoprim-sulfamethoxazole (TMP-SMX; 2, 2.1%) and levofloxacin (22, 23.4%). All-cause in-hospital mortality was 29.6% (29 patients). The highest mortality, 53.8%, was observed in pulmonary sources of bacteremia. CONCLUSIONS: Although TMP-SMX continues to have reliable activity in our cohort, we noted resistance to TMP-SMX in patients with recent TMP-SMX exposure, including a case with developing resistance to TMP-SMX while on therapy.
format Online
Article
Text
id pubmed-6988836
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-69888362020-02-03 Stenotrophomonas Bacteremia Antibiotic Susceptibility and Prognostic Determinants: Mayo Clinic 10-Year Experience Hamdi, Ahmed M Fida, Madiha Abu Saleh, Omar M Beam, Elena Open Forum Infect Dis Major Article BACKGROUND: Stenotrophomonas maltophilia is a gram-negative, opportunistic infection that is usually hospital-acquired and associated with high morbidity and mortality. The reported increase in S. maltophilia infections is presumed to be due to an increase in the population at risk. METHODS: We retrospectively reviewed 10-year data for S. maltophilia bacteremia in hospitalized adults at our institution to determine the population at risk, sources of infection, common complications, antimicrobial susceptibility profiles, and clinical outcome trends over the past decade. RESULTS: Among the 98 patients analyzed, the most common source of infection was catheter-related (62, 63.3%). Most isolates (61, 65%) were resistant to ceftazidime; fewer were resistant to trimethoprim-sulfamethoxazole (TMP-SMX; 2, 2.1%) and levofloxacin (22, 23.4%). All-cause in-hospital mortality was 29.6% (29 patients). The highest mortality, 53.8%, was observed in pulmonary sources of bacteremia. CONCLUSIONS: Although TMP-SMX continues to have reliable activity in our cohort, we noted resistance to TMP-SMX in patients with recent TMP-SMX exposure, including a case with developing resistance to TMP-SMX while on therapy. Oxford University Press 2020-01-19 /pmc/articles/PMC6988836/ /pubmed/32016126 http://dx.doi.org/10.1093/ofid/ofaa008 Text en © The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Major Article
Hamdi, Ahmed M
Fida, Madiha
Abu Saleh, Omar M
Beam, Elena
Stenotrophomonas Bacteremia Antibiotic Susceptibility and Prognostic Determinants: Mayo Clinic 10-Year Experience
title Stenotrophomonas Bacteremia Antibiotic Susceptibility and Prognostic Determinants: Mayo Clinic 10-Year Experience
title_full Stenotrophomonas Bacteremia Antibiotic Susceptibility and Prognostic Determinants: Mayo Clinic 10-Year Experience
title_fullStr Stenotrophomonas Bacteremia Antibiotic Susceptibility and Prognostic Determinants: Mayo Clinic 10-Year Experience
title_full_unstemmed Stenotrophomonas Bacteremia Antibiotic Susceptibility and Prognostic Determinants: Mayo Clinic 10-Year Experience
title_short Stenotrophomonas Bacteremia Antibiotic Susceptibility and Prognostic Determinants: Mayo Clinic 10-Year Experience
title_sort stenotrophomonas bacteremia antibiotic susceptibility and prognostic determinants: mayo clinic 10-year experience
topic Major Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6988836/
https://www.ncbi.nlm.nih.gov/pubmed/32016126
http://dx.doi.org/10.1093/ofid/ofaa008
work_keys_str_mv AT hamdiahmedm stenotrophomonasbacteremiaantibioticsusceptibilityandprognosticdeterminantsmayoclinic10yearexperience
AT fidamadiha stenotrophomonasbacteremiaantibioticsusceptibilityandprognosticdeterminantsmayoclinic10yearexperience
AT abusalehomarm stenotrophomonasbacteremiaantibioticsusceptibilityandprognosticdeterminantsmayoclinic10yearexperience
AT beamelena stenotrophomonasbacteremiaantibioticsusceptibilityandprognosticdeterminantsmayoclinic10yearexperience